MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash collections
from financial...
$3,354,750K
(12.45%↑ Y/Y)
Other royalty cash
collections
$114,021K
(4.75%↑ Y/Y)
Interest received
$34,308K
(-26.19%↓ Y/Y)
Distributions from equity
method investees
$13,396K
(0.00%↑ Y/Y)
Cash collections
from intangible...
$720K
(-95.08%↓ Y/Y)
Net cash provided by
operating activities
$2,489,823K
(-10.08%↓ Y/Y)
Canceled cashflow
$1,027,372K
Net change in cash
and cash...
-$310,330K
(-168.65%↓ Y/Y)
Canceled cashflow
$2,489,823K
Proceeds from sales of
available for sale debt...
$510,553K
Distributions from equity
method investees
$105,149K
(344.77%↑ Y/Y)
Proceeds from equity
securities
$34,723K
(-64.78%↓ Y/Y)
Proceeds from available
for sale debt...
$21,226K
(7.28%↑ Y/Y)
Proceeds from issuance of
long-term debt, net of...
$1,954,475K
(32.85%↑ Y/Y)
Proceeds from revolving
credit facility
$1,275,000K
Contributions from
non-controlling interests -...
$5,697K
(30.67%↑ Y/Y)
Contributions from legacy
non-controlling interests - r&d
$220K
(-70.55%↓ Y/Y)
Development-stage funding
payments
$452,000K
Payments for operating
and professional...
$288,138K
(21.98%↑ Y/Y)
Interest paid
$276,291K
(73.15%↑ Y/Y)
Payments for employee
epas
$10,943K
Net cash used in
investing activities
-$1,614,180K
(39.73%↑ Y/Y)
Canceled cashflow
$671,651K
Net cash (used
in)/provided by financing...
-$1,185,973K
(-428.39%↓ Y/Y)
Canceled cashflow
$3,235,392K
Acquisitions of financial
royalty assets
$1,697,729K
(-32.25%↓ Y/Y)
Milestone payments
$271,313K
(261.75%↑ Y/Y)
Purchases of available for
sale debt securities
$175,000K
(16.67%↑ Y/Y)
Acquisition of businesses,
net of cash acquired
$74,416K
Purchases of equity
securities
$58,427K
(-6.52%↓ Y/Y)
Other
$8,946K
(538.74%↑ Y/Y)
Repayment of revolving
credit facility
$1,275,000K
Repurchases of class a
ordinary shares
$1,227,383K
(434.46%↑ Y/Y)
Repayment of long-term
debt
$1,000,000K
Dividends to shareholders
$378,253K
(0.47%↑ Y/Y)
Distributions to legacy
non-controlling interests -...
$354,901K
(-2.04%↓ Y/Y)
Distributions to continuing
non-controlling interests
$167,475K
(33.81%↑ Y/Y)
Debt issuance costs
and other
$16,563K
(31.29%↑ Y/Y)
Other
-$1,790K
(80.17%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
1-svg
Royalty Pharma plc (RPRX)
1-svg
Royalty Pharma plc (RPRX)